Clinical Trials Logo

Clinical Trial Summary

The investigators hypothesize that implementing an electronic health record-based early warning system for severe infections (severe sepsis) will decrease the time to antibiotic order. The study will consist of an algorithm which will monitor lab values, vital signs, and nursing documentation for signs of severe sepsis. When these criteria are met, an alert will be delivered via the electronic health record to a nurse and doctor and simultaneously an alert via pager to another nurse. The investigators plan to randomize which patients will generate these alerts and analyze the data after collecting information for approximately 6 months which will be sufficient to detect a 10% difference in the two patient groups.


Clinical Trial Description

Sepsis is the leading cause of mortality at Stanford Hospital and ranks only 54th out of 119 hospitals according to UHC data with approximately 60 episodes of documented sepsis per quarter. Based on some preliminary data, there is concern that sepsis is both being recognized late and not treated in a timely enough fashion. In fact, there are evidence and expert guidelines that suggestion-delaying antibiotics in a patient with septic shock can increase mortality by 6.7% per hour (1C recommendation in severe sepsis by the Surviving Sepsis Campaign authors). As part of a hospital wide initiative to improve our treatment of sepsis and ultimately reduce sepsis-related mortality, an EHR-based clinical decision support (aka BPA) will be implemented. This BPA will be an algorithm that will alert practitioners and trigger clinical workflow after criteria are met. Criteria include lab values, vital signs and nursing flow sheet descriptions of perfusion (Table 1). The algorithm will alert when, in a 24 hour period, three criteria from the manifestation group, one criteria from the suspected infection group and one criteria from the organ dysfunction group. Note that one variable (eg creatinine > 2) can fulfill criteria in more than one group. Figure 1 contains details of proposed EHR workflow. After criteria are met, whomever is next in the chart with RN or MD user-type, will receive an interruptive alert via the EHR; simultaneously a page will automatically be sent by the EHR to a crisis nurse who will assess the patient and notify the primary MD and RN.

Electronic early warning systems and predictive analytic tools lack rigorous evaluation and standardization. There are literature demonstrating unintended consequences and even harms from the implementation of electronic health records and clinical decision support tools. As such, this is a situation of clinical equipoise in which it is unclear whether this quality improvement initiative will benefit patient care or not. To evaluate this question, the severe sepsis BPA will be initiated in a randomized fashion with each patient randomly assigned to either potentially generate this alert as described above or to generate this alert silently such that only quality improvement staff will be aware that criteria have been met via the EHR.

This is a randomized, single-blind prospective quality improvement study. Patients will be randomized by encounter to have the BPA visible or invisible during hospital admission. If visible, the alert will display to the primary nurse and physician and send a page to a crisis nurse when BPA criteria are met. If invisible, the alert will be triggered but will be invisible to the care team (only visible to quality improvement staff via the EHR)

- Inclusion criteria

o Admitted to Stanford Hospital (inpatient or observation status) to any medical or surgical service for at least 24 hours during the period of the study

- Exclusion criteria

o Admitted to an intensive-care level service (MICU, SICU, CVICU, CCU)

- While ideally we will make this available to ICU patients, the alert is likely to be far less specific in ICU patients and less clinically useful given the high level of care (eg 1:1 nursing and hourly vital signs).

o Patient code status is DNR/C (comfort care only)

- These patients would not be appropriate to treat with antibiotics and aggressive care generally give the comfort care goals of care.

o Emergency Department patients (may be included in the near future)

- Primary endpoints

o Percentage of patients receiving antibiotics within three hours

- Secondary endpoints

- Percentage of patients with hypotension or lactate >= 4 who received at least 30 ml/kg fluid

- Rate of 3 hour sepsis bundle completion (serum lactate, blood cultures, antibiotics)

- Length of hospital stay

- Cost of hospital stay per day and overall cost

- Mortality at hospital discharge

- Sample size and duration

- Based on prior studies, we predict a 10-15% difference in one or more primary endpoints (see Sawyer et. Al, Crit Care Med. 2011 March, 39:469)

- We therefore anticipate enrolling 1500 patients, an estimated 150 of whom will have true sepsis, over approximately six months, to achieve 80% power.

- Analysis will compare endpoints among all patients in the treatment and control groups

- Early stopping will be decided by an oversight committee which will review data at 3 months. If there is statistically significant different of more than 10% between groups, the study will be terminated early and in discussion with hospital quality and safety committee, use whichever strategy is superior for all patients in the hospital. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver)


Related Conditions & MeSH terms


NCT number NCT02376842
Study type Interventional
Source Stanford University
Contact
Status Completed
Phase N/A
Start date November 2014
Completion date March 2015

See also
  Status Clinical Trial Phase
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Completed NCT02539147 - Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis N/A
Completed NCT01929772 - German Lactat Clearance in Severe Sepsis N/A
Completed NCT01932814 - Acute Kidney Injury in Septic Critically Ill Patients : Are Aminoglycosides Really Harmful? N/A
Completed NCT01449721 - Preemptive Resuscitation for Eradication of Septic Shock N/A
Active, not recruiting NCT01162109 - Zinc Therapy in Critical Illness Phase 1
Not yet recruiting NCT01211899 - 4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock N/A
Completed NCT00934011 - Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections N/A
Recruiting NCT00335907 - Protocol-driven Hemodynamic Support for Patients With Septic Shock N/A
Completed NCT00463645 - Investigation of Correlation Between Interstitial and Arterial Blood Glucose Concentrations in Septic Patients N/A
Completed NCT02361528 - GM-CSF to Decrease ICU Acquired Infections Phase 3
Completed NCT02734550 - (1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis N/A
Completed NCT02973243 - The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III N/A
Terminated NCT03895853 - Early Metabolic Resuscitation for Septic Shock Phase 2
Completed NCT01945983 - Early Use of Norepinephrine in Septic Shock Resuscitation N/A
Completed NCT01598831 - Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy Phase 3
Enrolling by invitation NCT02258984 - Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial N/A